| -0.01 / -0.25%|
Synta Pharmaceuticals Corp. discovers, develops and commercializes novel pharmaceutical products. It is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with cancer and other severe medical conditions. Its lead drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer and in a broad development program including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia. In addition, the company developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.
|Keith R. Gollust||Executive Chairman & Chief Executive Officer|
|Christine Redmond||Vice President-Operations & Program Management|
|Keith S. Ehrlich||CFO, Vice President-Finance & Administration|
|Vojo Vukovic||Chief Medical Officer & Senior Vice President|
|Iman El-Hariry||Vice President-Clinical Research|